TITLE

Chemical bombshell explodes in tumour cells

AUTHOR(S)
Bradley, David
PUB. DATE
August 1991
SOURCE
New Scientist;8/31/90, Vol. 131 Issue 1784, p20
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
Focuses on the design of an anticancer compound which could become a model for drugs capable of treating solid tumors. Use of nitrogen mustard as the cell-killing component; Effects of the compound.
ACCESSION #
10553101

 

Related Articles

  • Anti-tumour activity and toxicity of the new prodrug 9-aminocamptothecin glucuronide (9ACG) in mice. Prijovich, Z.M.; Chen, B.-M.; Leu, Y.-L.; Chern, J.-W.; Roffler, S.R. // British Journal of Cancer;5/20/2002, Vol. 86 Issue 10, p1634 

    Cancer chemotherapy is limited by the modest therapeutic index of most antineoplastic drugs. Some glucuronide prodrugs may display selective anti-tumour activity against tumours that accumulate β-glucuronidase. We examined the toxicity and anti-tumour activity of 9-aminocamptothecin...

  • Pharmacological Strategies to Increase the Antitumor Activity of Methylating Agents. Tentori, Lucio; Graziani, Grazia // Current Medicinal Chemistry;Jul2002, Vol. 9 Issue 13, p1285 

    Among methylating agents of clinical interest, temozolomide is a novel antitumor compound that has raised particular interest due to its acceptable safety profile and activity against tumors poorly responsive to conventional chemotherapy, such as malignant glioma and metastatic melanoma....

  • How to starve a tumor. Gorman, Christine // Time International (South Pacific Edition);1/9/95, Issue 2, p37 

    Reports on the development of two proteins which act as blocking agents that dissolve blood vessels that provide nourishment to tumors. Scripps Research Institute scientists' discovery of a single biochemical switch that triggers the growth of blood vessels in almost all tumors in laboratory...

  • NEOPLASMS.  // Physician Assistants' Prescribing Reference;Winter2010, Vol. 17 Issue 4, p239 

    The article offers information on antineoplastic agents with details on generic name, brand name, and legal category.

  • Trastuzumab: A Viewpoint by Suhail M. Ali. Ali, S.M. // BioDrugs;1999, Vol. 12 Issue 2, p136 

    Reports on the use of trastuzumab in the treatment of tumors expressing HER2. Indications of use; Interaction between antineoplastic therapy and HER2 expression; Drawbacks of trastuzumab therapy.

  • Trastuzumab: A Viewpoint by Mark Pegram. Pegram, M. // BioDrugs;1999, Vol. 12 Issue 2, p136 

    Comments on the use of trastuzumab in the treatment of HER2-expressing tumors. Drug properties; Dilemmas facing clinicians with regard to trastuzumab treatment.

  • FDA Panel Holds out Hope to pNET Patients.  // Bioworld Week;4/18/2011, Vol. 19 Issue 16, p4 

    The article reports that the two drugs Afinitor from Novartis Pharmaceuticals Corp. and Sutent from Pfizer Inc. have gained approval from the Oncologic Drugs Advisory Committee, causing Food and Drug Authority (FDA) to hope for an effective treatment for pancreatic neuroendocrine tumors (pNET).

  • Patient-Derived Tumor Xenografts Are Susceptible to Formation of Human Lymphocytic Tumors. Bondarenko, Gennadiy; Ugolkov, Andrey; Rohan, Stephen; Kulesza, Piotr; Dubrovskyi, Oleksii; Gursel, Demirkan; Mathews, Jeremy; O'Halloran, Thomas V.; Wei, Jian J.; Mazar, Andrew P. // Neoplasia;Sep2015, Vol. 17 Issue 9, p735 

    Patient-derived xenograft (PDX) tumor models have emerged as a new approach to evaluate the effects of cancer drugs on patients' personalized tumor grafts enabling to select the best treatment for the cancer patient and providing a new tool for oncology drug developers. Here, we report that...

  • Camptothecins: A Review of Their Chemotherapeutic Potential. Ulukan, H.; Swaan, P.W. // Drugs;2002, Vol. 62 Issue 14, p2039 

    Camptothecin analogues and derivatives appear to exert their antitumour activity by binding to topoisomerase I and have shown significant activity against a broad range of tumours. In general, camptothecins are not substrates for either the multidrug-resistance P-glycoprotein or the...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics